EQT Acquires Majority Stake in Adalvo

For over twenty years, the Aztiq team and I have been dedicated to founding and nurturing enterprises that make a significant impact on healthcare. Our mission has always been to make life-changing, high-quality medications accessible to more patients around the world.

Today, we are proud to announce that EQT has acquired a majority stake in one of our key enterprises, Adalvo. Since its inception in 2018, Adalvo has grown into a leading B2B pharmaceutical company, thanks to the dedication of its team.

Adalvo has enabled drugmakers to build comprehensive portfolios that meet their customers' needs. As the company transitions to new ownership, we remain committed and engaged. We look forward to collaborating with EQT to guide Adalvo through its next phase of growth, serving even more partners and patients.

It has been a privilege to be part of Adalvo’s journey from the beginning. With EQT's strategic leadership, I am confident that Adalvo will achieve even greater heights. I will continue to support and cheer on Adalvo’s journey.

Together, we will strive to make high-quality, affordable healthcare accessible to all.